Proinflammatory Cytokines, Immune Response and Tumour Progression
- Derek J. Chadwick Organizer,
- Jamie A. Goode
Published Online: 7 OCT 2008
DOI: 10.1002/0470856734.ch7
Copyright © Novartis Foundation 2004
Book Title

Cancer and Inflammation: Novartis Foundation Symposium 256
Additional Information
How to Cite
Spadaro, M. and Forni, G. (2008) Proinflammatory Cytokines, Immune Response and Tumour Progression, in Cancer and Inflammation: Novartis Foundation Symposium 256 (eds D. J. Chadwick and J. A. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470856734.ch7
Publication History
- Published Online: 7 OCT 2008
- Published Print: 23 JAN 2004
ISBN Information
Print ISBN: 9780470855102
Online ISBN: 9780470856734
- Summary
- Chapter
Summary
Tumour cells naturally secrete proinflammatory cytokines and chemokines to interact with the microenvironment and regulate neoangiogenesis. The repertoire of factors thus produced shapes tumour progression. However, experiments in the mouse have shown that injection of a low pharmacological dose of a proinflammatory cytokine or chemokine into the microenvironment increases the inflammatory reaction so enormously that locally activated leukocytes inhibit or eradicate the tumour. Massive shrinkage of recurrent head and neck squamous cell carcinomas (SCC) and prevention of recurrences after surgical removal of a primary SCC follow perilymphatic administration of low doses of interleukin (IL)2, while low daily doses of IL12 markedly delay carcinogenesis in transgenic mice predestined to die of mammary carcinomas and keep them tumour-free for long periods. The reaction elicited by proinflammatory cytokines evidently has a great potential in tumour control.
